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PURPOSE. Primary open-angle glaucoma (POAG) and primary congenital glaucoma (PCG) with
Mendelian inheritance are caused by mutations in at least nine genes. Utilizing whole-exome
sequencing, we examined the disease burden accounted for by these known Mendelian
glaucoma genes in a cohort of individuals with advanced early-onset POAG.
METHODS. The cases exhibited advanced POAG with young age of diagnosis. Cases and
examined local controls were subjected to whole-exome sequencing. Nine hundred ninety-
three previously sequenced exomes of Australian controls were called jointly with our
dataset. Qualifying variants were selected based on predicted pathogenicity and rarity in
public domain gene variant databases. Case–control mutational burdens were calculated for
glaucoma-linked genes.
RESULTS. Two hundred eighteen unrelated POAG participants and 103 nonglaucomatous
controls were included in addition to 993 unexamined controls. Fifty-eight participants
(26.6%) harbored rare potentially pathogenic variants in known glaucoma genes. Enrichment
of qualifying variants toward glaucoma was present in all genes except WDR36, in which
controls harbored more variants, and TBK1, in which no qualifying variants were detected in
cases or controls. After multiple testing correction, only MYOC showed statistically significant
enrichment of qualifying variants (odds ratio [OR] ¼ 16.62, P ¼ 6.3131016).
CONCLUSIONS. Rare, potentially disease-causing variants in Mendelian POAG genes that showed
enrichment in our dataset were found in 22.9% of advanced early-onset POAG cases. MYOC
variants represented the largest monogenic cause in POAG. The association between WDR36
and POAG was not supported, and the majority of POAG cases did not harbor a potentially
disease-causing variant in the remaining Mendelian genes.
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Glaucoma is the leading cause of preventable irreversibleblindness worldwide, with a well-known genetic contri-
bution.1 Vision damage in glaucoma manifests as visual field
loss secondary to optic nerve injury.2 The disease can be
defined as open angle or angle closure depending on the width
of the iridocorneal angle.3 Primary open-angle glaucoma
(POAG) is the most common subtype among Caucasians with
a 2.37% prevalence in this population,1 with intraocular
pressure (IOP) and age being the most significant risk factors.4,5
Primary open-angle glaucoma can be subclassified into high-
tension glaucoma (HTG), where untreated IOP is more than
two standard deviations above the population mean, and
normal-tension glaucoma (NTG), where untreated IOP remains
within the normal range (IOP < 22 mm Hg). Similarly, POAG
can be subclassified by age of onset, from less than 4 years for
primary congenital glaucoma (PCG), between 4 and around 40
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years for early-onset or juvenile-onset POAG (JOAG), to over 40
years for typical POAG. An autosomal dominant mode of
inheritance is present in a proportion of individuals with
POAG. Estimates place the percentage of Mendelian inherited
POAG explained by known causative genes at around 5%.6 The
Online Mendelian Inheritance in Man (OMIM) database (www.
omim.org; accessed October 17, 2016; in the public domain)
documents seven genes (MYOC, *601652; OPTN, *602432;
CYP1B1, *601771; WDR36, *609669; ASB10, *615054; NTF4,
*162662; and TBK1, *604834) with potentially disease-causing
variants in POAG and two (CYP1B1, *601771 and LTBP2,
*602091) in PCG. Additionally, the GLC1C locus has since been
linked to the gene IL20RB (interleukin 20 receptor subunit
beta) via Sanger sequencing.7
Family-based linkage studies on large affected pedigrees
have revealed a number of genes linked to POAG with
Mendelian inheritance. Only three genes (MYOC, OPTN,
CYP1B1) with disease-causing single nucleotide variants
(SNV) and one with copy number variants (TBK1) have been
unequivocally replicated in discrete glaucoma cohorts. The
first and the most prevalent gene discovered in familial POAG is
myocilin (MYOC).8,9 The prevalence of heterozygous MYOC
disease-causing variants is around 4% in Caucasian POAG
populations overall.8,10 It accounts for a greater proportion in
the JOAG subset, with a prevalence of 17% in Australia10 and
up to 36% in the United States.11 Disease-causing variants are
predominantly located within the third exon and are likely a
result of founder effects within European Caucasian popula-
tions.12–14 The MYOC glaucoma phenotype is characterized by
a young age of onset with high IOP.10,11 Optineurin (OPTN)
was the second gene to be linked to Mendelian POAG.15 In
contrast to MYOC, disease-causing OPTN variants impart a
glaucoma phenotype with normal IOP and are rarer, with
percentages ranging from 1.5% to 3.5% of the NTG popula-
tion.16,17 In multiple study cohorts, only the heterozygous
p.Glu50Lys variant in OPTN has been definitively proven to be
disease causing15–18 via a gain-of-function mechanism, thereby
explaining the low frequency and lack of variant diversity seen
in OPTN-related glaucoma. Both MYOC and OPTN variants are
transmitted in an autosomal dominant manner. TBK1 (TANK-
binding kinase 1) has been linked to POAG in the form of
autosomal dominant copy number duplication or triplication,
with replication in multiple Caucasian POAG cohorts.19,20
However, the incidence of TBK1 copy number variant in
glaucoma is very rare, accounting for only 0.8% (10 out of 1222
NTG cases) of individuals with NTG in Caucasian and Asian
populations.19–24 CYP1B1 (cytochrome P450, family 1, sub-
family B, polypeptide 1) disease-causing variants have been
linked to both PCG and JOAG.25–27 Biallelic CYP1B1 variants
transmitted in an autosomal recessive manner are involved in
PCG, whereas both biallelic and heterozygous variants have
been involved in POAG with a lower frequency rate.
Deleterious CYP1B1 variant frequency is highly variable
between ethnicities: Prevalence rates of CYP1B1 variants have
been reported as 4.6% in a French POAG case cohort,26 4.62%
in a Taiwanese Chinese JOAG case cohort,28 6.8% in an
Australian JOAG case cohort,27 and 11.1% in an Iranian POAG
case cohort.29 Like CYP1B1, variants in LTBP2 (latent
transforming growth factor beta binding protein 2) transmitted
in an autosomal recessive manner were originally linked to
PCG,30,31 with heterozygous variants later suggested in
POAG.32 Other genes linked to POAG but with less certainty
include ASB10, NTF4, and WDR36.33–35 ASB10 (ankyrin
repeat and SOCS box containing 10) and WDR36 (WD repeat
domain 36) have shown variability in their replication, with
subsequent studies reporting no statistically significant differ-
ence in the frequency of potentially pathogenic variants
between POAG cases and controls within cohorts of similar
ethnicities.36–39 Heterozygous variants in NTF4 (neurotrophin
4) have been suggested to be a rare cause of POAG, ranging
from 0.3% in Chinese cohorts40 to 2.26% in German cohorts,34
but were not associated with POAG in US41 and Indian
cohorts.42
Here we used whole-exome sequencing (WES) to examine
the disease burden of these nine known Mendelian POAG
genes in a cohort of participants with the most severe
glaucoma from a population-based database, the Australian
and New Zealand Registry of Advanced Glaucoma (ANZRAG).
METHODS
This study adhered to the principles listed in the revised
Declaration of Helsinki and the Australian National Health and
Medical Research Council (NHMRC) statement of ethical
conduct in research involving humans. Ethical approval was
obtained from the Southern Adelaide and Flinders University
Clinical Research Ethics Committee. Written informed consent
was obtained from all participants following explanation of the
research. All peripheral blood samples were collected for
genomic DNA extraction as a part of the ANZRAG as previously
described.43
Participants
The individuals composing the study cohort were Caucasian
participants from the ANZRAG database, collected in a
prospective unselected manner and previously analyzed for
common disease-associated variants in genome-wide associa-
tion studies (GWAS).44–47 Participants with advanced glaucoma
and the youngest age at diagnosis with mean age at diagnosis
44.4 6 10.4 years were included in this study. Advanced
glaucoma was defined as a glaucomatous visual field loss
involving at least two of the four central fixation squares with a
pattern standard deviation of less than 0.5% on a reliable
Humphrey 24-2 field (Carl Zeiss, Dublin, CA, USA), or a mean
deviation of worse than 15 dB in the worse affected eye. For
participants without formal visual field testing, their best-
corrected visual acuity had to be worse than 20/200 owing to
glaucomatous damage. The less affected eye was also required
to have glaucomatous optic neuropathy as measured by a
reliable Humphrey 24-2 field, with corresponding neuroretinal
rim thinning. Participants with HTG or NTG were included.
High-tension glaucoma was defined as having a maximum
recorded untreated IOP of greater than 21 mm Hg. Individuals
with secondary glaucoma were excluded from this study.
Individuals with disease-causing MYOC variants detected on
capillary sequencing were not analyzed by WES10 (Supple-
mentary Table S1), but were included for analysis to enable
relative proportions of POAG cases potentially explained by
each individual gene to be assessed.
All local control participants were interviewed to exclude a
family history of glaucoma and further examined to exclude
glaucoma or phenotypic traits including cupping of the optic
disc, deficit on Humphrey visual field testing, and elevation of
IOP that could be related to glaucoma. A larger unexamined
control cohort from the Australian Osteoporosis Genetics
Consortium (AOGC)48 was included for in silico analysis. All
AOGC participants (n¼ 993) were females with either high or
low bone mass and were otherwise self-identified as healthy.
Whole-Exome Sequencing
DNA was extracted from peripheral blood samples using the
QIAamp DNA blood kit (Qiagen, Hilden, Germany) following
the manufacturer’s protocol. Samples were prepared with
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SureSelect Human All Exon V4 enrichment kit (Agilent, Santa
Clara, CA, USA) per manufacturer’s protocol for whole-exome
capture and enrichment. Enriched DNA was sequenced on a
HiSeq2000 (Illumina, San Diego, CA, USA) with 100 bp paired
end reads (Macrogen Next Generation Sequencing Services,
Marcogen, Inc.). Local controls served as both technical and
phenotypic controls. Raw sequencing data were used to
generate binary alignment map (BAM) files and joint-called
with previously sequenced AOGC exomes that were captured
with Nimblegen Human Exome Capture V2 (Roche, Basel,
Switzerland) and sequenced on the HiSeq2000 (Illumina) at the
University of Queensland Centre for Clinical Genomics,
Brisbane, Australia. FASTQ files were aligned to human genome
build hg19 with Novoalign (version 3.02.08; Novocraft
Technologies Sdn Bhd, Petaling Jaya, Selangor, Malaysia).
Duplicate reads were marked with Picard MarkDuplicates
(version 1.124; http://broadinstitute.github.io/picard; in the
public domain). Local indel realignment and base quality
recalibration were performed with GATK49 (version 3.2-2).
Variant calling of SNV and small indels was performed with the
UnifiedGenotyper module in GATK, and variant quality scores
were recalibrated according to the GATK Best Practices
Guidelines.50,51 Variant annotation was performed using
ANNOVAR52 software using refGene, SIFT53 (Sorting Intolerant
From Tolerant), PolyPhen2 HVAR54 (Polymorphism Phenotyp-
ing v2), NHLBI GO Exome Sequencing Project (ESP) (http://
evs.gs.washington.edu/EVS/; in the public domain), 1000
Genomes Project (http://www.1000genomes.org/; in the
public domain), and Exome Aggregation Consortium (ExAC)
databases (exac.broadinstitute.org/; in the public domain).
Bioinformatic Analysis
Whole exomes from all glaucoma cases not carrying patho-
genic MYOC variants (n ¼ 189) and controls (n ¼ 1096) were
analyzed concurrently. Only protein coding exonic and splicing
site variants were selected for analysis following filtering with
in-house UNIX codes. The quality control threshold was set at a
Genotype Quality (GQ) score of 20. In order to include only
potentially disease-causing variants, all variants with a minor
allele frequency (MAF) of greater than 0.01 in dbSNP, NHLBI
GO Exome Sequencing Project (ESP), 1000 Genomes Project,
and ExAC were excluded. Pathogenicity filtering further
removed all synonymous variants, and missense variants
considered ‘‘tolerated’’ or ‘‘possibly damaging’’ by both SIFT
and PolyPhen2 HVAR, respectively. The qualifying variants for
analysis consisted of all protein-truncating variants in the
canonical gene transcript, including nonsense, frameshift, and
essential splice site variants, as well as missense variants
predicted to be deleterious by either SIFT or PolyPhen2 HVAR.
Variants in nine Mendelian POAG genes, ASB10, CYP1B1,
IL20RB, LTBP2, MYOC, NTF4, OPTN, TBK1, and WDR36,
were selected. Of these genes, LTBP2 has been linked to PCG,
CYP1B1 to both PCG and POAG, and the rest to POAG only.
Variant loads per gene were calculated for the glaucoma case
and control cohorts by summing the minor allele counts of all
qualifying variants in the same gene and dividing by the
average number of captured alleles for those variants to adjust
for capture rate. Odds ratios were generated by comparing the
glaucoma variant load with the control using Fisher’s exact test
to calculate P values.
RESULTS
This study included 218 participants with advanced POAG
from the ANZRAG and 1096 controls (103 without clinical
features of glaucoma and 993 unexamined Australian controls).
There were 150 HTG and 68 NTG participants. The mean
maximum recorded IOPs of each group were 32.9 6 8.9 and
18.1 6 2.9 mm Hg, respectively. The mean age at diagnosis for
the POAG cohort was 44.4 6 10.4 years. Twenty-six HTG
participants and 3 NTG participants were found to carry MYOC
disease-causing variants upon capillary sequencing and were
excluded from WES. Whole-exome sequencing was performed
on the remaining 189 cases and 103 examined controls. The
mean percentage of mappable reads was 99.4%, with an
average total of 4.123109 on-target reads per sample, and an
average depth of 73 reads per target base. Coverage of at least
10-fold was achieved at an average of 97.9% of all targeted
exonic regions. Australian Osteoporosis Genetics Consortium
controls had an average depth of 24 reads per target base and
‡10-fold coverage of 75.1%.
Qualifying variants in known primary glaucoma genes (all
nine genes) were identified in 58 cases (58/218, 26.6%) and 128
controls (128/1096, 11.7%) generating an odds ratio of 2.74
(1.93–3.90, P¼ 1.013107) (Supplementary Table S2 shows all
variants found in glaucoma cases). Only one participant with
POAG carried qualifying variants in more than one gene, with
qualifying variants in both CYP1B1 and WDR36. Variants
(heterozygous) for MYOC accounted for most carriers of
qualifying variants in all the nine genes (26 or 17.3% of HTG,
3 or 4.4% of NTG, 29 or 13.3% of all POAG), and demonstrated
significant enrichment within the POAG cohort (odds ratio
[OR]¼ 16.62, Fisher’s P¼ 6.3131016) (Table). All other genes
except TBK1 and WDR36 exhibited nominal enrichment in
POAG; however, the difference was not statistically significant
(Table). No TBK1 SNV or indels were detected in the POAG
cohort, and only one SNV was detected in 1096 controls.
Primary congenital glaucoma caused by mutations in both
CYP1B1 and LTBP2 genes has an autosomal recessive pattern
of disease inheritance, although both heterozygous and
compound heterozygous variants have previously been report-
ed in POAG cohorts.27,32 Four cases carried two qualifying
variants in these genes. One participant was compound
heterozygous and two were homozygous for CYP1B1 qualify-
ing variants. Another participant was compound heterozygous
for LTBP2 qualifying variants. Another three and five partici-
pants were heterozygotes for qualifying variants in CYP1B1
and LTBP2, respectively. No control was homozygous or
potentially compound heterozygous for qualifying variants in
CYP1B1 (Fisher’s P ¼ 0.0047) or LTBP2 (Fisher’s P ¼ 0.17).
Carrier rates for CYP1B1 and LTBP2 in the control cohort are
shown in the Table.
WDR36 was the only gene to harbor more qualifying
variants in the control cohort than in cases (OR ¼ 0.52, 0.25–
1.09). For the remaining eight Mendelian POAG genes, a total
of 50 POAG cases (22.9%) carried qualifying variants. The
carrier rate for qualifying variants in each gene excluding
WDR36 and TBK1 in cases versus controls is shown in Figure
1. With WDR36 excluded, no cases carried qualifying variants
in multiple Mendelian POAG genes. The proportion of cases
carrying qualifying variants in each Mendelian POAG gene is
presented in Figure 2.
DISCUSSION
This study explored the genetic contribution of the nine
known primary glaucoma genes in 218 Caucasian POAG
participants from the ANZRAG with advanced disease and
young age at diagnosis. We examined odds ratios associated
with each gene to determine their relative contributions to
POAG cases and controls. Our results highlight the over-
whelming influence of MYOC among the known Mendelian
POAG genes, but emphasize that the majority of POAG cases
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are not accounted for by mutations in the known Mendelian
glaucoma genes. These unexplained cases are likely to be
accounted for by a combination of common GWAS alleles, rare
variants in glaucoma risk genes, noncoding variants not found
in WES, copy number variations, and large structural variations
that are difficult to detect.
The proportions of our POAG cases explained by individual
genes were largely in accord with previous publications,
despite differences in cohorts, sequencing methods, and
qualifying variant definitions. The prevalence of MYOC
disease-causing variants in advanced JOAG patients was
reported to be 17% in our previous study10 with an age at
diagnosis cutoff of 40 years. The current study includes all
MYOC JOAG participants (age at diagnosis less than 40 years)
from our previous study as well as more recently identified
MYOC participants up to 55 years old at diagnosis. In another
study in which the inclusion criterion for age at diagnosis was
even younger at 35 years,11 up to 36% of all JOAG was
accounted for by disease-causing variants in MYOC. Although
there was no strict limit to age at diagnosis in this study, the
mean age of our POAG cohort was older than the thresholds
for both previous studies but still relatively young for POAG at
44.4 6 10.4 years. Therefore, our finding of 13.30% prevalence
for MYOC glaucoma is in keeping with previous data.
In our POAG cohort, there was one NTG participant out of
68 (1.5%) who carried the OPTN p.Glu50Lys disease-causing
variant. This rate is comparable with that in other replication
studies on OPTN,16–18 albeit much less than that in the
Japanese discovery cohort (13.5%).15 Our data also demon-
strate the highly conserved nature of the OPTN gene, with only
one person in the control cohort (0.1%) carrying a qualifying
variant. This generated a highly skewed odds ratio toward NTG
cases for this gene (OR ¼ 16.33 [1.01–263.94]). However, this
was not statistically significant due to the rarity of qualifying
variants in cases. It should also be noted that the p.Glu50Lys
variant is suspected to be a gain-of-function variant.22 Like
copy number gains in TBK1, this may represent a pathogenic
mechanism that our filtering criteria are not well positioned to
detect.
Although CYP1B1 and LTBP2 were initially linked to
autosomal recessive PCG, there is evidence that heterozygous
variants in these two genes may contribute to POAG.32,55 In
CYP1B1, the proportion of POAG cases with qualifying
variants was 2.75% and was lower than in previous reports
in Caucasian populations in France (4.6%)26 and New Zealand
(6.1%).56 This difference may be in part due to the younger age
at diagnosis in the French JOAG study (median¼40, range, 13–
52), as our previous study examining the prevalence of
CYP1B1 variants in JOAG found a 6.8% rate.27 Additionally,
the three cases in the French study harbored a known
polymorphic variant, p.(Ala443Val), which brings their true
prevalence to 3.4%. The case cohort in the New Zealand study
included pseudoexfoliative glaucoma and ocular hypertension
as well as POAG suspects, which makes any direct comparison
TABLE. Numbers and Percentages of POAG Cases or Controls Carrying One or More Qualifying Variants in Nine Mendelian POAG Genes
Gene
Number of Individuals (%) OR (95% CI)
P Value
POAGPOAG HTG NTG Ctrl POAG HTG NTG
ASB10 4 (1.83) 1 (0.67) 3 (4.41) 7 (0.72) 2.59 (0.75–8.93) 0.93 (0.11–7.62) 6.4 (1.62–25.33) 0.124
IL20RB 1 (0.46) 1 (0.67) 0 0 NA NA NA 0.120
CYP1B1 6 (2.75) 4 (2.67) 2 (2.94) 18 (2.00) 1.39 (0.54–3.53) 1.34 (0.45–4.02) 1.48 (0.34–6.53) 0.142
LTBP2 6 (2.75) 4 (2.67) 2 (2.94) 14 (1.29) 2.17 (0.82–5.71) 2.1 (0.68–6.47) 2.32 (0.52–10.43) 0.069
MYOC 29 (13.30) 26 (17.33) 3 (4.41) 10 (0.91) 16.62 (7.97–34.67) 22.72 (10.7–48.22) 5 (1.34–18.61) 6.3131016
NTF4 3 (1.38) 3 (2.00) 0 11 (1.13) 1.22 (0.34–4.39) 1.78 (0.49–6.45) NA 0.731
OPTN 1 (0.46) 0 1 (1.47) 1 (0.09) 5.04 (0.31–80.91) NA 16.33 (1.01–263.94) 0.305
TBK1 0 0 0 1 (0.09) NA NA NA 1
WDR36 8 (3.67) 6 (4.00) 2 (2.94) 75 (6.86) 0.52 (0.25–1.09) 0.57 (0.24–1.32) 0.41 (0.1–1.71) 0.098
The data from 218 cases and 1096 controls are presented. Odds ratios were calculated using POAG cases versus all controls with Fisher’s exact
test for P value. Bold font indicates statistical significance. Ctrl, control; CI, confidence interval.
FIGURE 1. Carrier percentages of one or more qualifying variants in known glaucoma genes. The odds ratios of POAG cases versus controls are
shown above each column pair.
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less meaningful. The biallelic rate (compound heterozygous or
homozygous) in this study was 1.4%, which is similar to the
0.85% in the French study26 and 1.8% in the New Zealand
study.56
LTBP2 was originally discovered as the gene responsible for
PCG linked to the GLC3D locus.30 Since then, it has also been
implicated in POAG in a study of 42 Iranian individuals. The
prevalence of LTBP2 deleterious coding variants was found to
be 11.9% (5 out of 42) in the Iranian study.32 However, a WES
study failed to detect any deleterious LTBP2 variants in Chinese
POAG, JOAG, and PCG patients.57 The prevalence of LTBP2-
predicted pathogenic variants in our Australian cohort (2.8%)
was lower than the rate reported in the Iranian population.
Taken with the evidence from the Chinese study, the
prevalence rate of LTBP2 in POAG appears to be heavily
dependent on ethnicity, just like the prevalence rate of
CYP1B1.32,57
The relevance of ASB10 in POAG pathogenesis has been
debated. Rare nonsynonymous variants in ASB10 in POAG
have been reported in 6.0% of Caucasian POAG cases
compared with 2.8% of controls in a mixed cohort from the
United States and Germany.58 A later study of a smaller US
cohort (n ¼ 158)36 found a 7.0% rare nonsynonymous variant
rate in POAG cases, which was not significantly higher than the
3.7% in controls (n¼ 82). Within the Japanese population, one
study reported significant association of microsatellite poly-
morphisms in the GLC1F/ASB10 locus with NTG.59 A more
recent Pakistani study of 238 cases found a significant
association of ASB10 rare nonsynonymous variants in POAG
with 9.7% prevalence in cases compared to 1.3% in controls.60
However, the variants did not segregate in the familial cases,
and one variant identified in cases but not in the controls
(p.(Arg453Cys)) has an allelic frequency of 2.2% in the ExAC
population database, emphasizing the importance of large
control cohorts to avoid selection bias. The ASB10 variant
p.(Arg304Cys) found in 0.23% of our cases was previously
reported in 0.4% of cases in the Pakistani study.60 The other
three variants found in our study have not been previously
reported. Our variant rates in cases and controls were lower
than in both previous studies due to the additional qualifying
condition of predicted pathogenicity via software prediction
prior to analysis. In our cohort, there was skewing of ASB10
variants toward NTG cases, which is supportive of the findings
from the Pakistani study and the study of microsatellite
polymorphisms in the Japanese NTG cohort. Given the rarity
of predicted pathogenic variants in ASB10, larger case cohorts
will be required to definitively examine its role in POAG
pathogenesis.
The prevalence of NTF4 variants in our cases was
comparable to, albeit slightly lower than, the 1.7% reported
in the discovery cohort of European Caucasians.34 Multiple
groups have attempted to replicate these results with mixed
success. Case–control studies of European Caucasians41 and
Indians42 found a higher rate of NTF4 mutation carriers in
controls compared with POAG subjects. The control cohort
used in the European study41 was significantly younger than
the original discovery cohort and may include cases that
develop glaucoma later in life. The mean age of our cases was
even younger than in the discovery cohort used in the
European study. Our slightly lower prevalence rate may be
attributable to the stringent filtering with pathogenicity
prediction software and a possible ‘‘winner’s curse’’ in the
original discovery cohort. Meanwhile, two separate studies in
Chinese populations have identified low rates of nonsynon-
ymous variation in NTF4 from 0.3% to 0.6% in POAG cases and
none in controls, suggesting that it may be a rare cause of
POAG in Chinese people.40,61
In a Chinese WES study, the prevalence of WDR36 variants
was high and similar to MYOC; however, no controls were
sequenced.57 Our study found that WDR36 variants were the
second most frequent after MYOC, although by a large margin.
However, it is highly unlikely that WDR36 variants are
causative for POAG in our cohort of advanced glaucoma
participants given the higher prevalence of WDR36 variants in
our age-matched local controls and AOGC controls than in
POAG cases. Our findings are similar to those in several
previous studies that also reported no significant association
between WDR36 and glaucoma pathogenesis owing to the
high prevalence of coding variants in controls.37–39
The glaucoma locus GLC1C was originally mapped to 3q21-
q24 between markers D3S3637 and D3S1744.62 It was not
until 2014 that the culprit variant for the original linkage signal
was identified in IL20RB, p.(Thr104Met), via Sanger sequenc-
ing.7 The variant was reported to reduce receptor function in
primary dermal fibroblasts from patients. Human trabecular
meshwork cells expressed the IL20RB protein and demonstrat-
ed its upregulation in response to cytokine treatment,
indicating its role in aqueous outflow resistance in POAG.
However, IL20RB diseasing-causing variants are exceedingly
rare, with none identified in the 230 random POAG cases
screened in the American study.7 In this study, we report the
presence of one novel nonsynonymous variant, p.(Arg140Ter),
in 1 HTG case and no rare nonsynonymous variants in 1096
controls. Our results support the involvement of IL20RB in IOP
regulation.
No qualifying variants were found in TBK1 in our POAG
cohort and only 0.1% of the control population carried any
qualifying variant in the gene. Published work on TBK1
implicated copy number gain in glaucoma pathogenesis.19,20
Our data complement this evidence by showing an absence of
potential disease-causing TBK1 SNVs in our POAG cohort.
However, one could not exclude altogether the possibility that
TBK1 SNVs or indels may be responsible for POAG given the
rarity of disease-causing copy number variation in TBK1.
The estimate of monogenic burden in POAG is traditionally
reported at around 5%.6 Another WES study similar to this
study also found MYOC to be the gene with the largest genetic
contribution to POAG in a Chinese cohort.57 The Chinese WES
study57 of predominantly POAG cases (125 WES) stated that
8.9% of its cohort harbored a known monogenic cause, of
FIGURE 2. Comparative percentages of advanced POAG cases with one
or more qualifying variants in Mendelian glaucoma genes.
Contribution of Known POAG Genes in Early-Onset Disease IOVS j March 2017 j Vol. 58 j No. 3 j 1541
Downloaded From: http://iovs.arvojournals.org/pdfaccess.ashx?url=/data/journals/iovs/936100/ on 04/26/2017
which 5.6% carried WDR36 variants. The percentage of our
POAG cohort carrying variants in known glaucoma genes
(26.6%) was significantly higher than previous estimates of 5%6
and 8.9% from the Chinese WES study.57 This finding may be
largely due to our extreme disease phenotype selection,
skewed toward a younger age of disease onset, as is seen in
comparison of JOAG versus POAG cohorts.10,15 By selecting for
only the most severe POAG disease phenotype, we have
enriched our case cohort for genetic causes of POAG with
higher penetrance. This strategy maximizes our ability to
identify disease-causing variants, and has been valuable for
discovering common disease alleles with modest cohort
sizes.44 However, given the rarity of disease-causing variants
in most POAG-causing genes, our sample size was insufficiently
powered to detect statistically significant association in genes
other than MYOC.
The strength of our study lies in our study cohort and
experimental design. All our glaucoma cases had detailed
clinical examinations to ascertain their phenotypes. Our large
control cohort is matched to our cases on ethnicity, with a
local subset also having been clinically examined to ensure
absence of glaucoma phenotype. Whole-exome sequencing
was performed contemporaneously on both cases and
screened controls, thereby minimizing technical variability.
One drawback of our study design is the potential underre-
porting of non-MYOC variants in cases carrying MYOC variants.
As MYOC-positive cases were excluded from exome sequenc-
ing, the co-occurrence of variants in the other POAG genes
cannot be excluded. This scenario is likely to be rare, as the
frequency of cases potentially explained by genes other than
MYOC in this advanced POAG cohort is 9.2%, which equates to
an underestimation of non-MYOC variants by two to three
participants (9.6% of 29, assuming no excessive enrichment of
these variants in the MYOC cohort). Moreover, JOAG partici-
pants in ANZRAG with MYOC disease-causing variants have
been previously sequenced at the CYP1B1 locus, and none
carried disease-causing variants in the latter gene.27 Other
limitations of this study relate to WES. The ANZRAG cases and
controls were captured with a different enrichment protocol
from that for the AOGC controls. Although sequencing was
performed on the same platform, batch effects on top of
capture differences could confound our data. We attempted to
minimize this systematic error by employing joint-calling of
both datasets using the same bioinformatic pipeline. Addition-
ally, although our local 103 controls were clinically screened to
exclude glaucoma or its related endophenotypes, no ophthal-
mic clinical examination was performed on the 993 AOGC
controls. Therefore, it is likely the AOGC control cohort
harbors the background rate of POAG in the Caucasian
population at around 2.37%. This reduces the power of this
study to detect significant differences between our cases and
the AOGC controls.
In conclusion, the majority of genetic causes for POAG
remain unidentified. In our selective cohort of participants
with early-onset advanced disease; MYOC had the single
greatest influence on POAG, accounting for up to 13.3% of
all cases. A role for WDR36 variants in POAG was not
supported in our cohort. The other seven Mendelian POAG
genes did not show a significant enrichment of qualifying
variants in POAG cases, although they may additively account
for up to 9.6% of the POAG burden, providing an overall
prevalence of up to 22.9% for known glaucoma genes in
advanced early-onset POAG.
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